SCHEMBL21165029

SCHEMBL21165029

Cc1cc(C(O)CN2CCCC2)c(C)n1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.45
KDM4E B2RXH2 4/20 0.42
USP14 P54578 3/20 0.42
USP7 Q93009 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 1/20 0.41
USP5 P45974 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 4/20 0.39
NR1H4 Q96RI1 1/20 0.39
MAPT P10636 3/20 0.39
GAA P10253 2/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
OPRK1 P41145 3/20 0.38
SIGMAR1 Q99720 1/20 0.38
CACNA1G O43497 2/20 0.37
IGF1R P08069 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6921452 0.86 USP14 (0.56) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL19501173 0.86 SMN1; SMN2 (0.53) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL19749177 0.77 GAA (0.46) HPGDKDM4ESMN1; SMN2RAB9AALDH1A1
SCHEMBL23559540 0.76 SMN1; SMN2 (0.49) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL21165030 0.76 NOTUM (0.48) HPGDUSP14USP7SMN1; SMN2ALDH1A1
SCHEMBL23559501 0.75 SMN1; SMN2 (0.48) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL21165185 0.74 KDM4E (0.40) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL6922703 0.74 USP14 (0.76) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL23524472 0.73 SMN1; SMN2 (0.77) HPGDKDM4EUSP14USP7SMN1; SMN2
SCHEMBL10476938 0.66 UGCG (0.50) KDM4EALDH1A1MAPK1KMT2AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 HPGD 4170/4885KDM4E 2300/4885USP14 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.